Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
ACARIX.STthis companyAcarix AB (publ)	SEK 0.16	-6.28×	7.91×	41.02×	-6.37×	-225.0%	37.5%	-652.2%	-653.3%	-126.0%	-125.8%	-16.3%	0×	0.41×	0×	4.08×	0.0%	3	12.43	1	D+
ALZCUR.STAlzeCure Pharma AB	SEK 6.42	-4.26×	6.11×	0×	-3.24×	-92.8%	0.0%	0.0%	0.0%	-144.8%	-139.1%	-17.2%	0.16×	0.94×	-180.85×	2.33×	0.0%	5	15.15	3	B+
BOUL.STBoule Diagnostics AB	SEK 1.22	-49.1×	1.11×	0.38×	16.9×	-8578.3%	43.7%	0.9%	-0.8%	-2.3%	-0.7%	-2.2%	1.34×	8.83×	0.28×	1.09×	0.0%	3	0.3	2	C
CLS-B.STClinical Laserthermia Systems AB (publ)	SEK 1.77	-4.27×	2.55×	10.18×	-5.92×	-9742.7%	-165.8%	-165.8%	-238.0%	-59.7%	-43.6%	-20.2%	0×	0.82×	-308.57×	3.91×	0.0%	1	-0.88	1	C-
ELIC.STElicera Therapeutics AB (publ)	SEK 2.60	-13.74×	10.19×	0×	-12.25×	-80.7%	0.0%	0.0%	0.0%	-74.5%	-76.8%	-9.1%	0×	1.43×	-2,278.11×	6.75×	0.0%	1	32.08	1	C-
INTEG-B.STIntegrum AB (publ)	SEK 8.08	-3.96×	1.07×	2.01×	-4.23×	-809.2%	69.2%	-56.4%	-50.7%	-26.9%	-25.4%	-31.6%	0.02×	0.4×	-83.91×	2.77×	0.0%	1	4.67	2	C+
Peer median	—	-4.27×	2.55×	0.38×	-4.23×	-809.2%	0.0%	0.0%	-0.8%	-59.7%	-43.6%	-17.2%	0.02×	0.94×	-180.85×	2.77×	0.0%	1	4.67	2	—